Why Great Companies Don't Innovate by Accident

By John Q. Leonard | Leading Edge Bio

Innovation has become one of the most overused words in business.

Every biotechnology company claims to be innovative.

Every pharmaceutical company has an innovation initiative.

Every annual report highlights innovation as a core value.

Yet despite billions of dollars invested in research, digital transformation, venture funds, incubators, AI platforms, and corporate partnerships, sustained innovation remains remarkably elusive.

History is full of organizations that were once considered innovation leaders.

Polaroid.

Sun Microsystems.

Yahoo.

Nokia.

Hewlett-Packard.

BlackBerry.

Each produced extraordinary breakthroughs.

None were able to sustain them indefinitely.

The question is not why these companies failed to innovate.

The question is why innovation itself proved so difficult to sustain.

I believe the answer is surprisingly simple.

Innovation is not a department.

It is an architecture.

Every Company Has an Innovation Machine

Whether intentionally designed or not, every organization possesses an innovation machine.

This machine determines:

• Which ideas get noticed.

• Which problems deserve attention.

• Which projects receive funding.

• Which technologies get licensed.

• Which risks are tolerated.

• Which people are promoted.

• Which failures are forgiven.

• Which successes are repeated.

Collectively, these decisions define how an organization creates innovation.

Most companies never consciously design this machine.

Instead, it evolves organically through incentives, budgeting processes, reporting structures, and organizational politics.

Eventually, the architecture itself begins determining what kinds of innovation become possible.

Innovation Without Strategy Becomes Activity

Many organizations confuse innovation strategy with innovation initiatives.

Innovation labs.

Corporate venture funds.

Hackathons.

Open innovation portals.

Accelerators.

AI pilots.

External partnerships.

Internal incubators.

Rapid prototyping.

None of these are strategies.

They are tools.

A strategy answers a different question:

What kind of innovation creates competitive advantage for our organization?

Everything else should follow from that answer.

Without this clarity, organizations collect best practices without understanding the tradeoffs they introduce.

The result is an innovation portfolio that lacks coherence.

Innovation Systems Are Interdependent

One of the most common mistakes executives make is assuming they can borrow isolated practices from successful companies.

"We need an incubator."

"We need a venture arm."

"We need open innovation."

"We need AI."

Perhaps.

Perhaps not.

Innovation systems function much like biological systems.

Changing one component inevitably affects the others.

Creating a venture investment arm changes incentive structures.

Building external partnerships changes internal R&D priorities.

Investing in AI changes data governance requirements.

Adopting platform technologies changes portfolio strategy.

None of these decisions occur in isolation.

Every component must reinforce the others.

Architecture Determines Behavior

Organizations rarely behave exactly as leaders intend.

They behave exactly as they are designed.

If scientists are rewarded only for publishing papers...

They will publish papers.

If business development teams are rewarded only for closing transactions...

They will optimize transactions.

If portfolio committees reward low-risk programs...

High-risk innovation disappears.

If executives celebrate failure publicly but punish it privately...

Employees stop taking risks.

Culture is often discussed as something intangible.

Much of culture is simply architecture made visible.

Corning: An Innovation Machine Designed for Longevity

One of the most instructive examples comes from Corning.

For more than 170 years, Corning has repeatedly reinvented itself across entirely different industries.

Glass.

Optics.

Telecommunications.

Display technologies.

Life sciences.

Advanced materials.

At first glance, many of Corning's decisions appear old-fashioned.

A centralized research campus.

Heavy investment in fundamental science.

Domestic manufacturing.

Long research horizons.

Against conventional management wisdom, these decisions seem inefficient.

Viewed strategically, however, they form an exceptionally coherent innovation architecture.

Corning's strategy has always centered on solving extraordinarily difficult materials science problems.

That objective requires:

• Deep scientific expertise.

• Long-term research investment.

• Close collaboration across disciplines.

• Tight integration between research and manufacturing.

• Patience.

Every structural decision reinforces that mission.

The innovation machine was designed intentionally.

Biopharma Needs Its Own Innovation Architecture

Healthcare presents a unique challenge.

Scientific discovery is becoming increasingly decentralized.

Novel biology emerges from:

Academic laboratories.

Biotechnology startups.

AI companies.

Contract research organizations.

Patient foundations.

Government-funded consortia.

Global research networks.

No single organization can own all meaningful innovation.

Consequently, pharmaceutical companies are evolving from discovery organizations into innovation orchestrators.

Success increasingly depends on designing architectures capable of integrating external science as effectively as internal discovery.

The Next Generation Innovation Machine

Tomorrow's innovation architecture may look fundamentally different.

Instead of a linear pipeline, imagine a continuously learning ecosystem.

Discovery platforms.

AI-driven target identification.

Human genetics.

Real-world evidence.

Digital biomarkers.

Companion diagnostics.

Adaptive clinical trials.

Manufacturing intelligence.

Regulatory AI.

Commercial analytics.

Each component continuously informs the others.

Knowledge compounds rather than moves sequentially.

The organization becomes a learning system.

AI Changes the Architecture

Artificial intelligence is often described as another tool.

Its real impact may be architectural.

AI changes:

How hypotheses are generated.

How literature is synthesized.

How experiments are designed.

How molecules are optimized.

How clinical trials are executed.

How regulatory submissions are assembled.

How portfolios are prioritized.

Perhaps most importantly, AI compresses the time required for learning.

Organizations that learn faster increasingly outperform organizations that merely execute faster.

External Innovation Is No Longer Optional

One implication becomes increasingly difficult to ignore.

No organization can sustainably innovate alone.

The most valuable innovation architectures increasingly combine:

Internal discovery.

Strategic licensing.

Academic collaboration.

Platform technologies.

AI partnerships.

Manufacturing alliances.

Clinical networks.

Real-world data.

Innovation becomes less about ownership.

More about connectivity.

The strongest organizations become hubs within larger ecosystems.

Designing Your Innovation Machine

Every executive should periodically ask:

• What kinds of innovation does our organization naturally reward?

• What ideas consistently fail to receive funding?

• Which partnerships create disproportionate value?

• Which incentives unintentionally discourage experimentation?

• Are our organizational structures aligned with our strategy?

• Does every component of our innovation system reinforce the others?

If those answers feel disconnected, the architecture likely needs attention.

The Leading Edge Perspective

Throughout my career, working across discovery science, licensing, strategic partnerships, AI-enabled technologies, antibody platforms, cell and gene therapy, and commercialization, one lesson has become increasingly clear.

The organizations that consistently outperform their peers rarely possess dramatically better scientists.

Or larger budgets.

Or better technology.

They possess better-designed innovation systems.

They know what problems they exist to solve.

They align incentives around those priorities.

They partner intelligently.

They learn continuously.

Most importantly, they recognize that innovation is not a collection of isolated initiatives.

It is a carefully engineered architecture.

As artificial intelligence, systems biology, and platform technologies continue reshaping healthcare, competitive advantage will increasingly belong to organizations that intentionally design their innovation machines rather than simply adding new technologies to old operating models.

Because in the end, innovation is not about generating more ideas.

It is about building an organization capable of repeatedly transforming ideas into medicines that improve patients' lives.

Leading Edge Bio explores the intersection of scientific innovation, external innovation, strategic partnerships, commercialization, and corporate strategy. We share executive perspectives on the evolving biopharmaceutical ecosystem, helping leaders translate breakthrough science into meaningful partnerships, sustainable growth, and improved patient outcomes.

John Q. Leonard is Principal of Leading Edge Bio, where he writes about external innovation, strategic partnerships, business development, and the evolving intersection of science, technology, and commercialization across the global biopharmaceutical industry.